Protego Biopharma closed an oversubscribed $130 million Series B to advance PROT‑001, an oral candidate for AL (light‑chain) amyloidosis, toward a pivotal trial next year. The financing was led by established life‑science funds and included investors with prior rare‑disease expertise. PROT‑001 is a first‑in‑class small molecule designed to stabilize misfolded light chains and limit amyloid deposition. Protego positions the candidate as an alternative to antibody approaches that failed in recent pivotal studies. The capital injection extends Protego’s runway and funds the regulatory and clinical work needed for a registrational program in a high‑unmet‑need orphan indication.